---
schema_version: "secwatch.filing_event.v1"
accession: "0001070081-23-000063"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2023-10-26T23:59:59+00:00"
generated_at: "2026-06-09T07:49:41.567724+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PTC Therapeutics Q3 total revenues $196.6M (-9% YoY), net loss $133M; updates pipeline timelines

## Summary
- DMD franchise revenue $136M in Q3; full-year 2023 DMD guidance raised to $565-595M.
- Translarna net revenue $69M; CHMP re-examination expected Jan 2024; FDA type C meeting in Q4 2023.
- Sepiapterin NDA submission for PKU delayed to no later than Q3 2024; MAA to EMA in H1 2024.
- PTC518 HD trial enrollment ongoing; FDA requires 6-month safety data for US dosing.
- Total 2023 revenue guidance $940M-$1.0B; GAAP R&D+SG&A expenses $915-965M.

## SEC filing metadata
- accession: 0001070081-23-000063
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2023-10-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000107008123000063/0001070081-23-000063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000107008123000063/tmb-20231026x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001070081-23-000063
- JSON: https://secwatch.observer/filing/0001070081-23-000063.json
- Plain text: https://secwatch.observer/filing/0001070081-23-000063.txt

## Key facts
- Earnings Releases
  PTC THERAPEUTICS, INC. reported the third quarter ending September 30, 2023 results: revenue $196.6 million. Guidance reaffirmed.
  - Period: the third quarter ending September 30, 2023
  - Revenue: $196.6 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Total revenues were $196.6 million for the third quarter of 2023, compared to $217.1 million for the third quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070081/000107008123000063/0001070081-23-000063-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.